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SUMMARY. In many countries, first-generation protease
inhibitors (PIs)/peginterferon/ribavirin (P/R) still represent
the only treatment option for HCV-infected patients. Sub-
jects with advanced disease and previous failure to P/R
urgently need therapy, but they are under-represented in
clinical trials. All treatment-experienced F3/4 Metavir
patients who received boceprevir (BOC)+P/R in the Italian–
Spanish Name Patient Program have been included in this
study. Multivariate logistic regression analysis (MLR) was
used to identify baseline and on-treatment predictors of
SVR and adverse events (AEs). Four hundred and sixteen
patients, mean age 57.7 (range 25–78 years), 70% males,
69.5% (289/416) F4, 14% (41/289) Child–Pugh class A6,
24% (70/289) with varices and 42% (173/416) prior null
responders to P/R, were analysed. Overall, SVR rate (all
381 patients who received one dose of BOC) was 49%,
(58% in F3, 45% in F4, 61% in relapsers, 51% in partial,
38% in null responders, and 72% in subjects with
undetectable HCV-RNA at treatment-week (TW)8. Among
patients with TW8 HCV-RNA ≥ 1000 IU/L, SVR was 8%
(negative predictive value = 92%). Death occurred in 3
(0.8%) patients, while decompensation and infections were
observed in 2.9% and 11%, respectively. At MLR, SVR pre-
dictors were TW4 HCV-RNA ≥ 1log10-decline from base-
line, undetectable TW8 HCV-RNA, prior relapse, albumin
levels ≥3.5 g/dL and platelet counts ≥100 000/lL. Metavir
F4, Child-Pugh A6, albumin, platelets, age and female gen-
der were associated with serious and haematological AEs.
Among treatment-experienced patients with advanced liver
disease eligible for IFN-based therapy, TW8 HCV-RNA
characterised the subset with either high or poor likelihood
of achieving SVR. Using TW8 HCV-RNA as a futility rule,
BOC/P/R appears to have a favourable benefit–risk profile.
Keywords: boceprevir, cirrhosis, first-generation protease
inhibitors, hepatitis C, IFN-based therapy.
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adverse event; SVR, sustained virological response; TW, treatment week.
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INTRODUCTION
Hepatitis C virus -infected patients with advanced fibrosis
and cirrhosis still represent a therapeutic challenge in the
era of direct acting antiviral agents (DAAs) because of
lower SVR rates and poorer tolerability of therapy [1–6].
Nevertheless, a clear benefit in treating cirrhotic patients
exists. In many cases, the urgency to treat their disease
before they reach the decompensated stage (i.e. when IFN-
based antiviral therapies become contraindicated), is still
an unmet clinical need. In this rapidly changing field, safer
and more efficacious therapies are emerging, either with or
without IFN [7–12]. Nevertheless, in a very large number
of countries worldwide, first-generation protease inhibitors
(PIs), combined with the IFN-based regimen, remain the
only available option for these patients. To date, Boceprevir
(BOC) has been approved and marketed in 67 countries
(only 28 in 2013 and 1 in 2014) while it has been
approved, but not marketed yet in 14 other countries. As
a result, it is conceivable to speculate that, due to cost-con-
tainment policies or limited economic resources, new DAAs
will not be affordable soon either. However, while waiting
for new molecules, pivotal phase-3 clinical trials on BOC,
which included a small sample size of patients with cirrho-
sis and only a few with both null response and advanced
disease [3,6,13,14], resulted in insufficient data regarding
maximum utilization of BOC. Therefore, useful information
to guide clinicians in daily practice is needed.
Overall risk to benefit ratio of BOC/P/R treatment in cir-
rhotic patients was analysed using expanded data from 5
Phase-3 clinical trials [15]. Specifically, this study identified
baseline and on-treatment variables (in particular week 8
response) that could help predict response and guide clini-
cal decisions regarding BOC triple therapy for cirrhotic
patients, including decisions about discontinuation for futil-
ity [15]. As a matter of fact, this post hoc analysis included
a carefully selected population with well-compensated dis-
ease and, again, a small number of patients with prior null
response. Consequently, the results obtained in this study
are not fully representative of the real-life population. Some
data have indeed been obtained by the CUPIC study
[16,17], which evaluated triple combination regimens with
either telaprevir or BOC in a wider range of treatment-
experienced cirrhotic patients (many of whom would not
have qualified for pivotal trials). However, this study
included a very small number of prior null responders, as
well [16,17]. In addition, the safety profile reported in the
CUPIC study was restricted, mainly due to the considerable
number of included patients described as being incompati-
ble with IFN-based regimens [18,19].
Here, we report a detailed analysis on the International
BOC Name Patient Program (NPP), which was indepen-
dently carried out in Italian and Spanish qualified Centres.
This was the largest cohort of patients with advanced
fibrosis/cirrhosis and prior null response ever studied. The
information provided enhances the quality of BOC treat-
ment and, therefore, allows better management of these
patients while filling the time gap until the arrival of new
drugs. By a detailed assessment of efficacy and safety in all
different categories of patients, including the week 8
response value, as a predictor of SVR [15], we were able to
assess the number needed to treat (NNT) for each SVR
achieved.
PATIENTS AND METHODS
From March 2011 to September 2012, all treatment-expe-
rienced patients with HCV genotype 1a or 1b, advanced
fibrosis and compensated cirrhosis with or without portal
hypertension were enroled for this analysis. The patients
were treated in 74 centres in the context of the NPP and
each centre included at least three patients.
Baseline recorded data were: gender, age, histology, liver
stiffness by FS, oesophageal varices, quantitative HCV-RNA
with the Roche COBAS TaqMan or Abbot assays with a
lower limit of detection of 15 and 12 IU/mL [20,21],
respectively, HCV genotype and IL28B polymorphism.
Clinical and virological assessments were performed
every 4 weeks during therapy and at weeks 12 and 24 of
the follow-up period. Futility rule was applied by label.
At the time of inclusion, patient disease stage was re-
evaluated by liver stiffness measurement and by endos-
copy. Cirrhosis was defined on the basis of any one of the
following criteria: (i) liver biopsy performed prior to Day 1
of the study showing cirrhosis consistent with Metavir
score F4 or Ishak F5/6, (ii) presence of oesophageal vari-
ces and (iii) fibroScan, performed within 12 calendar
months of Day 1 of the study, showing cirrhosis (liver
stiffness ≥12.5 kPa) [22,23]. The diagnosis of advanced
liver fibrosis was performed on the basis of any one of the
following criteria: (i) liver biopsy, performed within
24 months of Day 1 of the study, showing fibrosis with
Metavir score F3 or Ishak F3/4 and (ii) fibroScan, per-
formed within 12 months of Day 1 of the study, showing
liver stiffness ≥9.5 and ≤12.5 kPa. In case of disagree-
ment between previous histology (F3) and liver stiffness
value, consistent with F4 at time of inclusion, the latter
was considered the right one. Written informed consent
was obtained from each patient before enrolment. The
protocol was carried out in accordance with the Declara-
tion of Helsinki and was approved by local Ethics
Committees.
Safety assessment was carried out every 4 weeks with
the recording of any AEs and serious AEs (SAEs; including
deaths and hospitalizations), and AEs leading to study drug
discontinuations. Laboratory assessments focused on anae-
mia, neutropenia and thrombocytopenia. EPO use and
blood transfusions were also recorded. The following
parameters were considered to potentially represent hepatic
decompensation: onset of ascites, encephalopathy, bleeding
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from oesophageal varices, jaundice, and sepsis (in the
context of declining liver function).
Virological failures and futility rules at week 12 and 24
were used according to the label.
Breakthrough was defined as an HCV-RNA ≥ 1 log
increase after an undetectable HCV-RNA. Relapse was
defined as the onset of de novo detectable HCV-RNA after
EoTR. SVR12 was defined as having undetectable
HCV-RNA 12 weeks after completion or discontinuation of
therapy.
Statistical analysis
The primary efficacy analysis was conducted on all
patients who received at least 1 dose of BOC/P/R, while
SVR12 rates (overall and according to fibrosis stage on all
patients who received at least 1 dose of P/R during lead-in
phase) were also provided. The relationship between base-
line and on-treatment factors and SVR was explored using
univariate and multivariate logistic regression analyses
(MLR). We used a back-wise variable selection, and only
variables for which the association remained statistically
significant were included in the final multivariable logistic
regression model. Stratified MLR analysis was also per-
formed by fibrosis score. Analyses were performed with the
SAS software (version 8.2; Cary, NC). All P-values were
two-sided. P < 0.05 was considered statistically significant.
RESULTS
Patient accounting and baseline characteristics
Four hundred and sixteen treatment-experienced patients
with HCV genotype 1a or 1b with advanced fibrosis or
compensated cirrhosis were enroled from 74 centres,
which enroled at least three patients in Italy and Spain.
Baseline characteristics of the 416 enroled patients (overall
and according to administration of BOC after the lead-in
phase) are shown in Table 1. Briefly, 381 (92%) patients
received at least one dose of BOC. In the remaining cases
(8%), treatment was stopped before starting triple therapy
due to poor tolerance to IFN and RBV. Mean age was
57.7 years (range 25–78). HCV genotype 1b (323/416,
77.6%) was the prevalent genotype. The majority of
patients (289/416, 69.5%) had F4 cirrhosis. In this latter
group, Child classes A5 and A6 accounted for 85.4%
(240/416) and 14.6% (41/416) of patients, respectively;
approximately, 25% (70/289) had oesophageal varices,
13.2% (55/416) had platelet counts ≤100 000/lL and
8.7% (34/416) had serum albumin levels ≤3.5 g/dL. Seven
patients (2.4%) in the F4 group had concurrent low albu-
min levels and low platelet counts. Regarding prior treat-
ment history: 42% of patients (173/416) were null
responders, 35% relapsers (145/416) and 23% partial
responders (96/416). IL-28B genotype was available for
Table 1 Baseline characteristics of 416 patients at study
entry
Patients
characteristics*
All patients
Received
boceprevir
P-
valueN (col. %) No Yes (row %)
Total patients 416 35 381 (91.6)
Country
Italy 280 (67.3) 13 267 (95.4) 0.0002
Spain 136 (32.7) 22 114 (83.8)
Gender
Male 291 (70.0) 21 270 (92.8) 0.18
Female 125 (30.0) 14 111 (88.8)
Age
<50 years 116 (28.4) 13 103 (88.8) 0.10
50–59 years 151 (37.0) 7 144 (95.4)
≥60 years 141 (34.6) 14 127 (90.1)
Metavir
F3 127 (30.5) 6 121 (95.3) 0.08
F4 289 (69.5) 29 260 (90.0)
Child class
A5 240 (85.4) 20 220 (91.7) 0.04
A6 41 (14.6) 8 33 (80.5)
Varices
No 209 (74.9) 25 184 (88.0) 0.37
Yes 70 (25.1) 5 65 (92.9)
FibroScan
<12.5 kPa 131 (36.9) 8 123 (93.9) 0.24
≥12.5 kPa 224 (63.1) 23 201 (89.7)
Albumin
Low
(≤3.5 g/dL)
34 (8.7) 6 28 (82.4) 0.10
>3.5 g/dL 357 (91.3) 28 329 (92.2)
Platelets
Low
(≤100 000/lL)
55 (13.2) 10 45 (81.8) 0.02
>100 000/lL 361 (86.8) 25 336 (93.1)
Genotype
1b 323 (77.6) 27 296 (91.6) 1.00
1a 93 (22.4) 8 85 (91.4)
Previous
response
Relapser 145 (35.0) 8 137 (94.5) 0.15
Partial
responder
96 (23.2) 7 89 (92.7)
Null responder 173 (41.8) 20 153 (88.4)
IL28
CC 28 (10.5) 2 26 (92.9) 0.51
CT 173 (64.5) 9 164 (94.8)
TT 67 (25.0) 6 61 (91.0)
*Some information is missing for few patients. Bold values
are statistically significant.
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268 (64.4%) patients. The CT genotype was the most pre-
valent (64.5%) one. Table S1 shows the characteristics of
the patients according to country of origin.
Efficacy
Overall, SVR12 rates on all enroled patients who received
at least 1 dose of P/R during the lead-in phase were
45.2%, (188/416), 55.1% in F3, (70/127) and 40.8% in
F4, (118/289), respectively.
Figure S1 shows the rate of undetectable HCV-RNA at
different week points during the full course of treatment
and after its discontinuation. Figure 1 shows the overall
EoTR, SVR12 and relapse rates, which were 62%, 49%
Fig. 1 EoTR, SVR12 and relapse rate overall and
according to fibrosis stage. All patients who received at
least one dose of BOC included in the study.
Fig. 2 SVR12 according to fibrosis stage and prior
response. All patients who received at least one dose of
BOC included in the study.
Table 2 Predictors of treatment failure among patients with undetectable HCV-RNA at TW8 and of treatment success
among those with detectable HCV-RNA at TW8
Overall F3 F4
No SVR SVR No SVR SVR No SVR SVR
TW8* (%)
Detectable 132 (68.4) 61 (31.6) 35 (60.3) 23 (39.7) 97 (71.9) 38 (28.1)
Undetectable 44 (27.7) 115 (72.3) 11 (20.0) 44 (80.0) 33 (31.7) 71 (68.3)
PPV, % 72.3 80.0 68.3
NPV, % 68.6 60.3 71.9
Overall F3 F4
No SVR SVR No SVR SVR No SVR SVR
TW8† (%)
>1000 44 (91.7) 4 (8.3) 13 (100) 0 (0.0) 30 (90.9) 3 (9.1)
<1000 131 (43.4) 171 (56.6) 33 (33.0) 67 (67.0) 99 (48.3) 106 (51.7)
PPV, % 56.6 67.0 51.7
NPV, % 91.7 100 90.9
Overall F3 F4
No SVR SVR No SVR SVR No SVR SVR
TW8‡ (%)
<3 log-decline 26 (89.7) 3 (10.3) 12 (92.3) 1 (7.7) 14 (87.5) 2 (12.5)
≥3 log-decline 148 (46.5) 170 (53.5) 34 (34.0) 66 (66.0) 114 (52.3) 104 (47.7)
PPV, % 53.5 66.0 47.7
NPV, % 89.7 92.3 87.5
*HCV-RNA status is missing for 29 patients; †HCV-RNA evaluation is missing for 31 patients; ‡Log-decline.
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and 20%, respectively. No difference was observed in EoTR
rate between F3 and F4 patients, while SVR12 was signifi-
cantly lower in cirrhotic patients (P = 0.02) due to the
higher relapse rate (P = 0.01) in this latter group of
patients. SVR12 rates by historical response and by fibrosis
stage are shown in Fig. 2. As expected, SVR12 rate was
higher in relapsers (61.3%), compared to partial (50.6%)
and null (37.9%) responders. None of the patients with
concurrent low albumin levels and low platelet counts
achieved SVR. Overall, a high proportion of patients
(72.3%) with undetectable HCV-RNA levels at treatment-
week (TW) 8 achieved SVR (PPV 72.3%, 68.3% in F4 and
80% in F3). On the contrary, very few patients (4/48,
8.3%) with detectable TW8 HCV-RNA ≥ 1000 IU/L
achieved SVR (NPV = 91.7%, 90.9% in F4 and 100% in
F3) (Table 2).
Of interest, among 98 patients without a 1-log-decline
in HCV-RNA at TW4, 20 had undetectable HCV-RNA
and 29 had HCV-RNA < 1000 IU/L at TW8, respec-
tively.
Several factors predicting the achievement of SVR, over-
all and by F3/F4, were identified with MLR. The factors
identified were historical response to P/R (relapser vs par-
tial responder and null responder), fibroScan (1 kPa
increase, as a continuous variable), platelet counts
(≤100 000/lL) and albumin levels (≤3.5 g/dL), HCV-
RNA ≥ 1 log10-decline from baseline at TW4, and unde-
tectable HCV-RNA at TW8, which were all independently
associated with SVR (Tables 3 and 4).
In both F3 and F4 patients, HCV-RNA at
TW8 ≥ 1000 IU/L (undetectable HCV-RNA as the standard
reference) was associated with the lowest likelihood of
attaining SVR (95% confidence interval (CI) 10.5–124; risk
ratio (RR) 36.1, P < 0.0001, Table 3). SVR12, according
to TW8 HCV-RNA is illustrated in Fig. 3. As mentioned,
residual viremia >1000 IU/L was associated with high like-
lihood of not achieving SVR, regardless of whether or not
HCV-RNA ≥ 3 log-decline was reached (Fig. 3). In particu-
lar, only 3 of 21 (14%) patients with TW8 HCV-
RNA > 1000 IU/mL attained SVR, irrespective of having
achieved HCV-RNA ≥ 3 log-decline.
At TW8, 45.2% (159/352) of patients had undetectable
HCV-RNA. Baseline characteristics associated with a low
likelihood to achieve this result were albumin levels and
prior null response (Table S2). In addition, female gender,
albumin levels and low platelet counts predicted treat-
ment failure in this group of patients, while predictors of
SVR in patients with HCV-RNA still detectable at TW8
Table 3 Univariate and Multivariate analysis for SVR12
Variable Reference
Univariate Multivariate*
P-valueRR (95% CI) RR (95% CI)
TW8 < 1000 IU/mL Undetectable 3.97 (2.45–6.41) 4.22 (2.49–7.16) <0.0001
TW8 ≥ 1000 ≥ 3 log-decline Undetectable 47.0 (6.10–362.) 40.29 (10.7–152.) <0.0001
TW8 ≥ 1000 < 3 log-decline Undetectable 32.7 (7.42–143.)
TW4 < 1 log-decline ≥1 log-decline 3.53 (2.04–6.11) 2.75 (1.23–6.14) 0.01
TW4 1 log-decline <1 log-decline 0.47 (0.26–0.86)
TW4 2 log-decline <1 log-decline 0.24 (0.12–0.46)
TW4 3 log-decline <1 log-decline 0.18 (0.08–0.44)
TW4 4 log-decline <1 log-decline 0.06 (0.02–0.23)
TW4 5 log-decline <1 log-decline 0.05 (0.01–0.24)
TW4 log-decline (continuous) Per log-decline 0.54 (0.44–0.65)
Male Female 0.64 (0.41–0.99)
Age ≥60 years <60 years 1.14 (0.73–1.77)
Metavir F4 F3 1.65 (1.07–2.55)
Metavir F4 Child A6 F4 – Child A5 3.55 (1.48–8.52)
FibroScan (≥12.5 kPa) <12.5 kPa 1.65 (1.05–2.60)
FibroScan (continuous) Per 1 kPa 1.04 (1.02–1.07) 1.05 (1.02–1.09) 0.003
Varices F4 – No varices 1.03 (0.57–1.86)
HCV genotype 1b 1a 0.89 (0.55–1.44)
Prior null Prior relapser 2.60 (1.62–4.17) 2.06 (1.24–3.44) 0.004
Prior partial Prior relapser 1.55 (0.90–2.66)
Albumin ≤3.5 g/dL >3.5 g/dL 4.80 (1.78–12.9) 5.16 (1.67–16.0) 0.004
PLT ≤100 000/lL >100 000/lL 3.44 (1.69–7.02) 3.51 (1.50–8.21) 0.004
Baseline viral load >800 000 ≤800 000 1.04 (0.67–1.61) –
*Only variables for which the association remained statistically significant were included in the final multivariable logistic
regression model (Back-wise variables selection). Bold values are statistically significant.
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were Child class A5 vs A6, high albumin levels and high
platelet counts, and favourable IL28B CC genotype (Table
S3).
Table S4 shows the rate of SVR among the 159 patients
with undetectable HCV-RNA at TW8 according to whether
or not they had received a full course of treatment. Inter-
estingly, 102 of 120 (85%) subjects who completed the full
course of treatment achieved SVR. Detailed information
describes the reasons for early discontinuation of treatment
as shown in Table S5.
NNT calculation
SVR12 and NNT for single SVR stratified by patient char-
acteristics at time of entry, TW8 response and F3/F4 stages
are reported in Table 5.
Safety and tolerability
Overall, 92 patients (24.1%) withdrew from all treat-
ments due to adverse events (Table 6). Serious adverse
events (i.e. events that resulted in death were life threat-
ening, resulted in persistent or clinically significant dis-
ability/incapacity or required hospitalization) occurred in
13.4% (51/381) of all patients. Overall, three patients
died (0.8%; 0 in F3, 0 in F4/CP A5 and 3 (7.3%) in F4/
CP A6) at weeks 6, 10 and 28. All deaths occurred in
the F4 group of 289 patients (1%) compared to 0 deaths
in the group of 127 F3 patients. The cause of death was
attributable, in all cases, to multiple organ failure follow-
ing the onset of severe infection and generalized sepsis
(Table 6). Overall, 11 patients (2.9%) had hepatic decom-
pensation, and all episodes were observed in cirrhotic
patients (3.8%). The frequency of serious adverse events
was higher in patients with more advanced disease and
in the Spanish cohort (Table S6). At MLR, Metavir F4,
Fig. 3 SVR according to treatment-week 8 virological
response. All patients who received at least one dose of
BOC included in the study.
Table 5 SVR12 and NNT in patients receiving at least one BOC dose according to baseline characteristics, fibrosis stage,
historical response and TW8 HCVRNA value
Variable
Total Metavir F3 Metavir F4
Patients SVR (%) NNT Patients SVR (%) NNT Patients SVR (%) NNT
All 381 188 (49.3) 2.0 121 70 (57.9) 1.7 260 118 (45.4) 2.2
Italy 267 128 (47.9) 2.1 100 57 (57.0) 1.8 167 71 (42.5) 2.4
Spain 114 60 (52.6) 1.9 21 13 (61.9) 1.6 93 47 (50.5) 2.0
TW8 Undetectable 159 115 (72.3) 1.4 55 44 (80.0) 1.3 104 71 (68.3) 1.5
TW8 < 1000 IU/mL 143 56 (39.2) 2.6 43 22 (51.2) 2.0 100 34 (34.0) 2.9
TW8 ≥ 1000 IU/mL 48 4 (8.3) 12.0 15 1 (6.7) 15.0 33 3 (9.1) 11.0
Prior relapser 137 84 (61.3) 1.6 47 29 (61.7) 1.6 90 55 (61.1) 1.6
Prior partial 89 45 (50.6) 2.0 31 19 (61.3) 1.6 58 26 (44.8) 2.2
Prior null 153 58 (37.9) 2.6 42 21 (50.0) 2.0 111 37 (33.3) 3.0
FibroScan <12.5 kPa 123 71 (57.7) 1.7 107 65 (60.7) 1.6 16 6 (37.5) 2.7
FibroScan ≥12.5 kPa 201 91 (45.3) 2.2 – 201 91 (45.3) 2.2
Albumin >3.5 g/dL 329 168 (51.1) 2.0 99 56 (56.6) 1.8 230 112 (48.7) 2.1
Albumin ≤3.5 g/dL 28 5 (17.9) 5.6 – 28 5 (17.9) 5.6
PLT >100 000/lL 336 177 (52.7) 1.9 121 70 (57.9) 1.7 215 107 (49.8) 2.0
PLT ≤100 000/lL 45 11 (24.4) 4.1 – 45 11 (24.4) 4.1
NNT, number needed to treat; None of the seven patients with both low albumin and low platelet counts had SVR.
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liver stiffness ≥12.5 kPa and Child class A6 were inde-
pendently associated with the occurrence of SAEs
(Table 7). Two other strong predictors of SAEs during
treatment with BOC were also lower platelet counts and
lower albumin levels at baseline with an OR of 2.39
(95% CI: 1.12–5.10) and of 3.42 (95% CI: 1.45–8.08),
respectively (Table 7). Details on hospitalization are sum-
marized in Table S7. Approximately 70% of patients had
bone marrow toxicity (Table 6). Table S8 shows the pro-
portion of patients who required reduction of IFN, RBV
or both. RBV dose reduction was associated with higher
SVR rates (P < 0.003), while IFN reduction had no effect
on SVR. In multivariate analysis, female gender, older
age (>60 years) and low platelet counts were associated
with increased risk of haematological adverse events
(Table 7).
Resistance-associated variants
NS3 genotype resistance testing by population sequencing
was performed in 15 patients failing triple therapy with
BOC (3 = GT-1a, 11 = GT-1b and 1 = GT-1 g) and in 4
patients with early treatment discontinuation for adverse
events (1 = GT-1a and 3 = GT-1b) (Table S9). Population
sequencing of the viral protease was performed after a
median (IQR) of 5 (5;34) days from the time of treat-
ment discontinuation or virological failure. Upon
sequencing, HCV-RNA had median (IQR) values of 5.1
(3.8–5.0) log IU/mL, ranging from 280 to
3 002 138 IU/mL. Overall, at least one resistance-associ-
ated variant (RAV) was found in 12 of 15 patients anal-
ysed at the time of virological failure. In particular, in
all patients that showed viral breakthrough during treat-
ment (N = 3) or relapse after reaching the end of treat-
ment (N = 4), the increase of viremia after achieving
undetectable HCV-RNA was associated with RAVs occur-
rence (Table S9). Conversely, among the eight patients
who discontinued treatment in accordance with BOC
stopping rules, the de novo development of RAVs was
exclusively observed in the 2 patients in whom the inter-
ruption was delayed by investigator decision and in 1
GT-1a patient presenting at baseline with the NS3 muta-
tion Q80K. The remaining 5 patients who discontinued
treatment after 12 weeks for virological failure did not
show de novo development of RAVs. One of them was
however infected by GT-1 g [24]. The characteristics of
de novo RAV mutations within the 10 patients experienc-
ing virological failure is described in Table S9. Among
the 4 patients who prematurely discontinued treatment
due to adverse events, 1 who delayed the discontinuation
of treatment despite the futility rule showed de novo
development of RAVs (R155K).
DISCUSSION
Boceprevir, in combination with P/R, was launched in Sep-
tember 2010. However, in several countries, it is still not
available. Since then, with the exception of the US and few
European countries, all other nations permitted this treat-
ment only for patients with more advanced liver disease,
mainly due to cost-containment measures. This limitation
is expected to be maintained for at least the next 2 years
in the vast majority of the world. In addition, it is well
known that achieving an SVR reduces the risk of HCC,
decompensation, and all-cause mortality in patients with
cirrhosis [25–27]. Therefore, deferring access to therapy in
these patients while waiting for all oral IFN-free regimens
might not be an option. However, the safety concern
reported in the CUPIC study [17], especially for patients
with severe portal hypertension and deteriorated liver func-
tion as well as lacking data in patients with previous null
response to P/R, suggest that additional, reliable informa-
tion to optimize BOC-based treatment in daily practice is
needed. Here, we show that, 50% of all F4 patients treated
with BOC/P/R can achieve an SVR. SVR rates were partic-
ularly high (69%) in patients with undetectable HCV-RNA
at TW8, as previously reported in a smaller number of
patients with such characteristics [18]; these patients
accounted for almost half of all treated cirrhotic popula-
tions. Furthermore, F3 patients with undetectable viral
load at TW8 achieved higher SVR rates (80%). The reason
why the rate of SVR in patients with F4 is lower, when
compared to F3 subjects, is easily explained by the higher
Table 6 Adverse events anytime during TW5-TW48
among 381 patients who received at least one dose of BOC
Adverse events during TW5-TW48 N (%)
Serious adverse events 51 (13.4)
Deaths 3 (0.8)
Sepsis, MOF 4 (1.1)
Infections 43 (11.3)
Hepatic decompensation 11 (2.9)
Haematological adverse events 265 (69.6)
Anaemia
Grade 2–3 (8.5 < Hb < 10 g/dL) 198 (52.0)
Grade 4 (Hb < 8.5 g/dL) 57 (15.0)
Neutropaenia
Grade 3 (500 < N < 750) 132 (34.7)
Grade 4 (N < 500) 46 (12.1)
Thrombocytopaenia
Grade 3 (25 000 < PLT < 50 000) 67 (17.6)
Grade 4 (PLT < 25 000) 6 (1.6)
Other events
Cutaneous adverse event 67 (17.6)
Cardiovascular adverse event 5 (1.3)
Cerebrovascular adverse event 11 (2.9)
Gastrointestinal adverse event 60 (15.8)
EPO 168 (44.1)
Transfusions 32 (8.4)
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relapse rate observed in this latter group of patients. Addi-
tional information provided by this study is that in patients
with undetectable HCV-RNA at TW8 who tolerated a full
course of therapy, SVR was extremely high (86%) and this
finding was observed in more than two-third of this group
of patients. Moreover, as there was no discontinuation
related to virological breakthrough in this group of sub-
jects, we may assume that the emergence of escape
mutants was absent or very low.
Previously, it was reported that SVR was more likely in
patients with advanced fibrosis/cirrhosis who had an HCV-
RNA decline ≥1.0 log at week 4 (end of the lead-in phase
with P/R) [18]. However, although this result was con-
firmed in our analysis, we found that approximately 50%
of patients with <1 log-decline at TW4 achieved undetect-
able HCV-RNA or <1000 IU/L at TW8. This data supports
the decision to start BOC therapy after the lead-in phase,
to avoid missing several SVRs in this poor IFN-sensitive
population.
Irrespective of the fibrosis stage, HCV-RNA ≥ 1000 IU/L
at TW8 was associated with a negligible rate of SVR (8%,
NPV = 92%). In agreement with the FDA and the Euro-
pean Commission (EC), which approved a revision of the
BOC Prescribing Information, (i.e. a futility rule to stop
therapy with BOC/P/R in all patients if TW8 HCV-RNA
levels are ≥1000 IU per mL was added), our results provide
a solid validation in support of this decision.
Additional predictors of SVR for F4 patients in the
MLR analysis included male gender, prior null response,
low albumin levels and low platelet counts. Supplemen-
Table 7 Predictors of serious or haematological adverse events during treatment with BOC (week 5 to week 48)
Serious events Haematological events
Events/patients (%) OR (95% CI) Events/patients (%) OR (95% CI)
Gender
Male 33/270 (12.2) 1.00 176/270 (65.2) 1.00
Female 18/111 (16.2) 1.39 (0.75–2.59) 89/111 (80.2) 2.16 (1.27–3.67)
Age
<50 years 10/103 (9.7) 1.00 60/103 (58.3) 1.00
50–59 years 21/144 (14.6) 1.59 (0.71–6.53) 98/144 (68.1) 1.53 (0.90–2.58)
≥60 years 19/127 (15.0) 1.64 (0.73–3.69) 101/127 (79.5) 2.78 (1.56–4.98)
Metavir
F3 5/121 (4.1) 1.00 81/121 (66.9) 1.00
F4 46/260 (17.7) 4.99 (1.93–12.9) 184/260 (70.8) 1.20 (0.75–1.90)
Child class (F4)
A5 35/220 (15.9) 1.00 155/220 (70.5) 1.00
A6 11/33 (33.3) 2.74 (1.22–6.16) 25/33 (75.8) 1.34 (0.57–3.11)
FibroScan
<12.5 kPa 7/123 (5.7) 1.00 79/123 (64.2) 1.00
≥12.5 kPa 37/201 (18.4) 3.74 (1.61–8.67) 145/201 (72.1) 1.44 (0.89–2.33)
Per 1 kPa increase 1.03 (0.99–1.06) 1.03 (0.99–1.06)
Varices (F4)
No 26/135 (19.3) 1.00 94/135 (69.6) 1.00
Yes 14/65 (21.5) 1.15 (0.56–2.39) 49/65 (75.4) 1.34 (0.68–2.62)
Genotype
1b 40/296 (13.5) 1.00 209/296 (70.6) 1.00
1a 11/85 (12.9) 0.95 (0.47–1.95) 56/85 (65.9) 0.80 (0.48–1.34)
Albumin
>3.5 g/dL 40/329 (12.2) 1.00 225/329 (68.4) 1.00
Low (≤3.5 g/dL) 11/52 (21.2) 3.42 (1.45–8.08) 40/52 (76.9) 1.39 (0.57–3.37)
Platelets
>100 000/lL 41/340 (12.1) 1.00 228/340 (67.1) 1.00
Low (≤100 000/lL) 10/41 (24.4) 2.39 (1.12–5.10) 37/41 (90.2) 5.13 (1.79–14.7)
Previous response
Relapser 22/137 (16.1) 1.00 105/137 (76.6) 1.00
Partial responder 12/89 (13.5) 0.82 (0.38–1.74) 66/89 (74.2) 0.88 (0.47–1.62)
Null responder 17/153 (11.1) 0.65 (0.33–1.29) 94/153 (61.4) 0.49 (0.29–0.81)
Bold values are statistically significant.
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tary information emerging from the study was that liver
stiffness, the value of which was found to be associated
with disease outcome [28], paralleled some well-estab-
lished surrogate markers of disease severity and portal
hypertension (i.e. Child class, platelet counts, and oesoph-
ageal varices) in predicting SVR. Consequently, this vari-
able may be proposed, as a useful tool to identify the
subgroup of patients not eligible for therapy with first-
generation PIs.
Although the clinical characteristics of F4 patients trea-
ted with BOC/P/R in the French Early Access Programme
were similar to those of patients in our study (median age
was 56.8 vs 57.7 years, proportion of male patients was
67.9% vs 69.5%), there were some differences between the
two cohorts. First of all, null responders were originally
excluded from the CUPIC study and, ultimately, 8% of
these subjects were enroled. Moreover, both mean baseline
platelet counts and serum albumin levels were lower in
the BOC–CUPIC arm (144 000/lL vs 165 000/lL and 4.8
vs 4.0 g/dL, respectively) compared to patients enroled in
our study, and NPP included 2.4% (vs 8.3% in CUPIC) of
patients with concomitant low baseline albumin levels and
platelet counts. Finally, the frequency of infection with
HCV genotype 1a was different (41% vs 22.4%). The pro-
portion of patients with oesophageal varices was also simi-
lar (37.6% vs 42%), but it should be noted that an upper
gastrointestinal endoscopy was performed in only 51.4% of
patients of the CUPIC population treated with BOC.
Despite these discrepancies, in agreement with the CU-
PIC study, we confirmed that the concurrent presence of
low albumin levels and platelet counts at baseline was a
strong predictor of poor response. Similarly, to the French
study, our survey showed that poor TW8 response (i.e.
HCV-RNA <3 log-decline compared to baseline) is associ-
ated with a low likelihood of SVR. Therefore, we may spec-
ulate that the two studies mutually validated themselves
and may be considered complementary in enhancing the
knowledge regarding this type of patients.
In summary, the present study provides the most
detailed analysis ever carried out in the largest group of
patients with advanced liver disease treated with BOC. The
attained results enable clinicians to evaluate, in each single
category of patients, predictors of both SVR (thus permit-
ting the calculation of the NNT) and severe complications
(both liver and haematological-related). The NNT in
patients with undetectable HCV-RNA at TW8 is extremely
favourable regardless of all negative baseline predictors.
Moreover, using this new TW8 futility rule, which our
study strongly validates, EPO and blood transfusions may
be spared, and the hospitalization rate may be reduced,
thus lowering the total cost of therapy. Finally, this may
be a way for clinicians to not deny BOC triple therapy ‘a
priori’ to all IFN-eligible patients, and thus safely prevent
exposure to an ineffective treatment in patients with a
potential high rate of adverse events.
In conclusion, this analysis assessed potential benefits
and risks of BOC treatment in a wide range of patients
with advanced liver disease. Using a simple combination of
baseline and on-treatment predictors, clinicians may easily
identify patients with a high likelihood of achieving SVR
and those at risk for severe complications. To fill the time
gap until all oral DAAs become available, an eight-week
BOC-based treatment may be proposed as a right option to
assess tolerability and likelihood of success of this therapy
in cirrhotic patients whose characteristics make them eligi-
ble for IFN-based regimens.
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SUPPORTING INFORMATION
Additional Supporting Information
may be found in the online version of
this article:
Figure S1: Virological response
during treatment and 12 weeks fol-
low-up. All patients who received at
least one dose of BOC included in the
study. Table S1: Baseline patient
characteristics at study entry, accord-
ing to country of origin.
Table S2: Baseline predictors of
HCV-RNA undetectable at TW8.
Table S3: Predictors of treatment
failure (no SVR) in patients with
undetectable HCV-RNA at TW8 or
treatment success (SVR) in patients
with detectable HCV-RNA at TW8.
Table S4: Details of patients with
undetectable HCV-RNA at week 8.
Table S5: Treatment course and
status of 381 patients who received
at least one dose of BOC.
Table S6: Adverse events anytime
during TW5-TW48 among 381
patients who received at least 1 dose
of BOC.
Table S7: Hospitalization (41 in 36
patients).
Table S8: SVR according to Ribavi-
rin and Peg/IFN reduction or inter-
ruption.
Table S9: NS3 genotypic resistance
test in patients experiencing virologi-
cal failure or early discontinuation of
treatment administration.
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